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TTo the Editor: Drugs interacting with hepatic cytochrome P450
(CYP) enzymatic activity can reduce clopidogrel-induced pharma-
codynamic (PD) effects (1). In particular, the proton pump
inhibitor (PPI)–clopidogrel interaction is a drug-specific effect
involving PPIs interfering with CYP2C19 activity (e.g., omepra-
ole) (2). Although the clinical implications of this interaction
emain controversial (3), these PD findings have prompted drug-
egulating authorities to issue a warning for the use of these drugs
4). Non-PPI gastric acid–suppressing strategies such as using H2
receptor antagonists (H2RAs) are treatment alternatives to PPIs
(1,4). H2RAs may also be differentiated according to their
CYP2C19 effects, whereas cimetidine, but not ranitidine, inhibits
YP2C19 activity and should be avoided in clopidogrel-treated
atients (1,4). To date, studies evaluating the impact of these
2RA on clopidogrel-induced PD effects are limited. Further, it
as been suggested that the development of adverse outcomes may
ccur only if patients reach thresholds of high platelet reactivity
HPR) (1,3). However, the impact of gastric acid–suppressing
trategies (PPI and non-PPI) on HPR rates remains unexplored.
The present prospective, randomized, open-label investigation
as conducted in stable patients on maintenance (1 month)
aspirin (81 mg/day) and clopidogrel (75 mg/day) therapy who were
randomly allocated to 7 to 10 days of treatment with: 1) omeprazole
(40 mg/day); 2) cimetidine (400 mg twice daily); or 3) ranitidine
(150 mg twice daily). Intragroup platelet function comparisons
were assessed, at baseline and after treatment, using the VerifyNow
P2Y12 (VN-P2Y12) system and light transmission aggregometry
(LTA) with adenosine diphosphate (20 M) stimuli, according to
tandard protocols (5). The VN-P2Y12 results are reported as
2Y12 reaction units (PRUs) and HPR is defined as PRU 230;
TA results are reported as maximal percentage platelet aggrega-
ion (MPA) and HPR is defined as MPA 50% (5).
A total of 60 patients (omeprazole [n  20], cimetidine [n 20],
or ranitidine [n  20]) met study inclusion criteria, provided written
consent and completed the study. Only omeprazole was associated
with an increase in platelet reactivity (VN-P2Y12 [189 107 vs. 212
106; p 0.009] and LTA [46.3 16.5 vs. 50.5 14.8; p 0.012]).
imetidine (VN-P2Y12 [213  116 vs. 226  107; p  0.21] and
TA (54.6  19.2 vs. 56.6  20.1; p  0.55]) and ranitidine
VN-P2Y12 [199  89 vs. 209  85; p  0.36] and LTA [46.5 
3.6 vs. 49.4 12.6; p 0.17])–treated patients had a nonsignificant
ncrease in platelet reactivity.
At baseline, a total of 23 (38.3%) and 31 (51.7%) patients had
PR defined by VN-P2Y12 and LTA, respectively. After gastric
cid–suppressing therapy, HPR using VN-P2Y12 was identified in
new patients: omeprazole (n  1), cimetidine (n  3), and *anitidine (n  2) (Fig. 1). These patients had a baseline PRU in
he 188 to 222 range. All patients with HPR at baseline except 2,
oth in the ranitidine group, remained above the PRU 230
hreshold. Using LTA, HPR was identified in 7 new patients:
meprazole (n  2), cimetidine (n  2), and ranitidine (n  3).
hese patients had baseline MPA in the 44% to 49% range. All
atients with HPR at baseline except 2, one treated with ranitidine
nd the other with cimetidine, remained above the MPA 50%
hreshold.
Many controversies have emerged surrounding the clinical
mplications of the PPI–clopidogrel interaction, fueling tremen-
ous debate given that PPIs have been recommended to reduce the
isk of gastrointestinal (GI) bleeding, an important predictor of
dverse outcomes (1,4). Although not as effective as PPIs, raniti-
ine may represent a treatment alternative in patients at low risk of
I bleeding, whereas cimetidine, an inhibitor of CYP2C19, should
ot be used (1,4). The present investigation shows that although
latelet reactivity significantly increased after omeprazole therapy,
hese effects were modest and did not reach statistical significance
ith cimetidine and ranitidine. Given that PD studies have shown
n increased risk of atherothrombotic events in patients with HPR,
t has been suggested that drug interactions may be clinically
eaningful only if these thresholds are reached (1,3). This study
howed that in patients with baseline platelet reactivity below these
hresholds HPR could develop irrespective of a gastric acid–
uppressing strategy. Importantly, all these patients had baseline
latelet reactivity within a range that was borderline to the HPR
hreshold. These findings may explain why changes in platelet
eactivity after gastric acid–suppressing therapy, albeit modest,
ay have prognostic implications in some patients but not in
thers. Population differences with an impact on platelet reactivity
ay contribute to the disparities in outcomes from clinical studies
ssessing these drug–drug interactions (1,3,5).
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Comparative Analysis of the
HAS-BLED Score With Other Bleeding Risk Scores,
Using Estimates of Net Reclassificationation ImprovementTo the Editor: We thank Drs. Rosenstein and DiMaggio for their
comments. We agree that estimates of net reclassification
improvement (NRI) and integrated discrimination improve-
ment (IDI) offer potentially useful analytic methods offering
incremental information relative to the c-statistic. Based on
their suggestions, we have calculated these statistics to comple-
ment the results provided in Table 7 of our paper (1), based on
he low-, moderate-, and high-risk categorizations resulting
rom the different bleeding risk schema. Table 1 summarizes the
results in terms of NRI and IDI, which together with our other
analyses presented in the original paper, would reinforce the
incremental utility of the HAS-BLED index over these other
schemas, with the exception of the score by Shireman et al. (2),
which is based on the NRI. As emphasized, the HAS-BLED
score also has the advantage of simplicity. We concur with Drs.
Rosenstein and DiMaggio that the NRI and IDI methodology
should be considered in the assessment of future contributions
as we seek to optimize the predictive accuracy of bleeding risk
prediction for patients with atrial fibrillation undergoing anti-
coagulation.
We also agree that bleeding risk with the new oral antico-
agulant agents may be different from warfarin, and our original
paper presents the risk factors for bleeding in warfarin-only
patients (Table 6 [1]) and the comparison against other scores
in warfarin-only patients (and not in combination with ximela-
gatran users, as implied in their letter).
As Drs. Rosenstein and DiMaggio suggest, further analyses
of the HAS-BLED scores in “real-world” nontrial populations
Statistical Comparison of the NRI and IDI Between HAS-BLED and Other ConTable 1 Statistical Comparison of the NRI and IDI Between HAS-BLED a
Difference in Predicted Probability of an Event
HAS-BLED Versus Patients With Event Patients Without Event
Shireman et al. (2) 0.644 0.025 0
HEMORR2HAGES (3) 0.400 0.015 0
Beyth et al. (4) 0.797 0.031 0
Kuijer et al. (5) 0.850 0.033 0would reinforce the usefulness of this score in the nontrial
cohorts, and our ongoing analyses in such ‘real world’ cohorts
again confirm the consistency of the usefulness of this score in
assessing bleeding risk in patients with atrial fibrillation (6).
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